JP2025001671A5 - - Google Patents

Info

Publication number
JP2025001671A5
JP2025001671A5 JP2024155116A JP2024155116A JP2025001671A5 JP 2025001671 A5 JP2025001671 A5 JP 2025001671A5 JP 2024155116 A JP2024155116 A JP 2024155116A JP 2024155116 A JP2024155116 A JP 2024155116A JP 2025001671 A5 JP2025001671 A5 JP 2025001671A5
Authority
JP
Japan
Prior art keywords
mutations
peptide epitopes
mutation
peptide
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024155116A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025001671A (ja
Filing date
Publication date
Priority claimed from JP2020572793A external-priority patent/JP2021529750A/ja
Application filed filed Critical
Publication of JP2025001671A publication Critical patent/JP2025001671A/ja
Publication of JP2025001671A5 publication Critical patent/JP2025001671A5/ja
Pending legal-status Critical Current

Links

JP2024155116A 2018-06-27 2024-09-09 個別化がんワクチンエピトープの選択 Pending JP2025001671A (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201862690441P 2018-06-27 2018-06-27
US62/690,441 2018-06-27
US201862757045P 2018-11-07 2018-11-07
US62/757,045 2018-11-07
US201962814200P 2019-03-05 2019-03-05
US62/814,200 2019-03-05
US201962855311P 2019-05-31 2019-05-31
US62/855,311 2019-05-31
JP2020572793A JP2021529750A (ja) 2018-06-27 2019-06-27 個別化がんワクチンエピトープの選択
PCT/US2019/039521 WO2020006242A1 (en) 2018-06-27 2019-06-27 Personalized cancer vaccine epitope selection

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020572793A Division JP2021529750A (ja) 2018-06-27 2019-06-27 個別化がんワクチンエピトープの選択

Publications (2)

Publication Number Publication Date
JP2025001671A JP2025001671A (ja) 2025-01-08
JP2025001671A5 true JP2025001671A5 (enExample) 2026-02-03

Family

ID=68986808

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020572793A Pending JP2021529750A (ja) 2018-06-27 2019-06-27 個別化がんワクチンエピトープの選択
JP2024155116A Pending JP2025001671A (ja) 2018-06-27 2024-09-09 個別化がんワクチンエピトープの選択

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020572793A Pending JP2021529750A (ja) 2018-06-27 2019-06-27 個別化がんワクチンエピトープの選択

Country Status (10)

Country Link
US (1) US20210268086A1 (enExample)
EP (1) EP3813848A4 (enExample)
JP (2) JP2021529750A (enExample)
KR (1) KR20210038886A (enExample)
CN (1) CN113365639A (enExample)
AU (1) AU2019293244B2 (enExample)
CA (1) CA3104673A1 (enExample)
MX (1) MX2021000193A (enExample)
SG (1) SG11202012770RA (enExample)
WO (1) WO2020006242A1 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3134131T3 (en) 2014-04-23 2022-02-07 Modernatx Inc Nucleic acid vaccines
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
WO2017070601A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (vzv)
MD3718565T2 (ro) 2015-10-22 2022-09-30 Modernatx Inc Vaccinuri împotriva virusului respirator
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
CN108430456B (zh) 2015-10-22 2022-01-18 摩登纳特斯有限公司 癌症疫苗
CA3007955A1 (en) 2015-12-10 2017-06-15 Modernatx, Inc. Lipid nanoparticles for delivery of therapeutic agents
US12128113B2 (en) 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
JP6983455B2 (ja) 2016-09-14 2021-12-17 モデルナティーエックス, インコーポレイテッド 高純度rna組成物及びその調製のための方法
AU2017345766A1 (en) 2016-10-21 2019-05-16 Modernatx, Inc. Human cytomegalovirus vaccine
CN110167587A (zh) 2016-11-11 2019-08-23 摩登纳特斯有限公司 流感疫苗
EP3551193A4 (en) 2016-12-08 2020-08-19 Modernatx, Inc. NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
EP3555289A1 (en) 2016-12-13 2019-10-23 ModernaTX, Inc. Rna affinity purification
US11229668B2 (en) * 2017-02-07 2022-01-25 Nantcell, Inc. Maximizing T-cell memory and compositions and methods therefor
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
MA47787A (fr) 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
WO2018187590A1 (en) 2017-04-05 2018-10-11 Modernatx, Inc. Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
WO2019036683A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. ANALYTICAL METHODS BY HPLC
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
CN111212905A (zh) 2017-08-18 2020-05-29 摩登纳特斯有限公司 Rna聚合酶变体
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof
AU2019345067A1 (en) 2018-09-19 2021-04-08 Modernatx, Inc. High-purity peg lipids and uses thereof
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
JP2022521094A (ja) 2019-02-20 2022-04-05 モデルナティエックス インコーポレイテッド 共転写キャッピング用rnaポリメラーゼバリアント
CN113874502A (zh) 2019-03-11 2021-12-31 摩登纳特斯有限公司 补料分批体外转录方法
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
CN113521269A (zh) 2020-04-22 2021-10-22 生物技术Rna制药有限公司 冠状病毒疫苗
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
WO2022150717A1 (en) 2021-01-11 2022-07-14 Modernatx, Inc. Seasonal rna influenza virus vaccines
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
IL311304A (en) 2021-09-13 2024-05-01 Oncodna A method for creating personal neoantigens from a patient's growth
EP4148146A1 (en) 2021-09-13 2023-03-15 OncoDNA Method to generate personalized neoantigens of a tumor of a patient
KR102753583B1 (ko) * 2021-11-11 2025-01-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
WO2023154478A1 (en) * 2022-02-11 2023-08-17 Washington University Methods of assessing cancer
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
WO2024014770A1 (ko) * 2022-07-14 2024-01-18 엠큐렉스 주식회사 mRNA 백신 및 치료제의 제조를 위한 변형된 RNA
CN120225259A (zh) * 2022-10-31 2025-06-27 磨石生物公司 组合组无细胞dna监测
EP4648793A1 (en) 2023-01-11 2025-11-19 ModernaTX, Inc. Personalized cancer vaccines
WO2025146078A1 (en) * 2024-01-04 2025-07-10 Everest Medicines (China) Co., Ltd. Cancer vaccines and uses thereof
US20250232833A1 (en) * 2024-01-13 2025-07-17 Noergaard Anders Kaare Cyclin D1 Based Cancer Vaccine
WO2025171182A1 (en) 2024-02-08 2025-08-14 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
CN120209073B (zh) * 2025-05-28 2025-09-23 北京立康生命科技有限公司 一种有利于抗原呈递的间隔肽

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3892295T3 (pl) * 2011-05-24 2023-07-24 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe
EP2914728B1 (en) * 2012-11-01 2020-07-08 Factor Bioscience Inc. Methods and products for expressing proteins in cells
BR112015025460B1 (pt) * 2013-04-07 2024-01-02 The Broad Institute, Inc. Método para a produção de uma vacina personalizada contra a neoplasia para um indivíduo diagnosticado como tendo uma neoplasia, vacina personalizada e uso da mesma
EP3294324A1 (en) * 2015-05-13 2018-03-21 Agenus Inc. Vaccines for treatment and prevention of cancer
WO2017020026A1 (en) * 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
CN108430456B (zh) * 2015-10-22 2022-01-18 摩登纳特斯有限公司 癌症疫苗
RU2768829C2 (ru) * 2017-02-01 2022-03-24 МОДЕРНАТиЭкс, ИНК. Противораковые рнк-вакцины

Similar Documents

Publication Publication Date Title
US20250249084A1 (en) Alphavirus antigen vectors
RU2019127381A (ru) Противораковые рнк-вакцины
JP2025063273A5 (enExample)
JP2021529750A5 (enExample)
AU2017363308B2 (en) Viral delivery of neoantigens
AU2018254526B2 (en) Neoantigen identification, manufacture, and use
TW202000907A (zh) 共有抗原
Toes et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells
AU2016264623B2 (en) Shared neoantigens
Sonaje et al. Self‐assembled pH‐sensitive nanoparticles: a platform for oral delivery of protein drugs
JP2024517731A5 (enExample)
CN120435550A (zh) 一种由多个kras变异肽连接而成的抗原肽、编码该抗原肽的核酸及其用途
JP2022502416A (ja) ネオエピトープを選択する方法
Chang et al. Targeting and specific activation of antigen‐presenting cells by endogenous antigen‐loaded nanoparticles elicits tumor‐specific immunity
CN111328420B (zh) 用于预防和治疗微卫星不稳定(msi)癌症的基于共有肿瘤新抗原的通用疫苗
WO1998059244A1 (en) Identification of mhc binding peptides
CN109890408A (zh) 新表位疫苗组合物及其使用方法
JP2006510718A (ja) 免疫療法としての酵母ベースのワクチン
WO2021092095A1 (en) Neoantigen vaccine therapy
Lu et al. Folate‐conjugated micelles and their folate‐receptor‐mediated endocytosis
Yu et al. A nanoparticle-based anticaries vaccine enhances the persistent immune response to inhibit Streptococcus mutans and prevent caries
Zhou et al. Identification of Enhanced Vaccine Mimotopes for the p15E Murine Cancer Antigen
MX2008011245A (es) Metodos y composiciones para la proteina a35r de virus de enfermedades pustulosas.
US20220160800A1 (en) Methods for inducing an immune response against neoantigens
CA2430621A1 (en) Vaccine composition containing transforming growth factor alpha